These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36087944)

  • 1. Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm.
    Valent P
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2375-2377. PubMed ID: 36087944
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of mepolizumab in hypereosinophilic syndromes: The position and proposals of the national reference center for hypereosinophilic syndromes].
    Kahn JE; Lefèvre G; Groh M
    Rev Med Interne; 2023 Apr; 44(4):155-157. PubMed ID: 36997273
    [No Abstract]   [Full Text] [Related]  

  • 3. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
    Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Treatment for Hypereosinophilic Syndrome.
    Aschenbrenner DS
    Am J Nurs; 2021 Mar; 121(3):23. PubMed ID: 33625006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Mepolizumab on the Lungs in a Boy with Hypereosinophilic Syndrome.
    Armoni Domany K; Shiran SI; Adir D; Lavie M; Levin D; Diamant N; Gut G; Benor S
    Am J Respir Crit Care Med; 2020 Jul; 202(2):e34-e35. PubMed ID: 32150442
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
    J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of a 4-year-old boy with mepolizumab for lymphocytic hypereosinophilic syndrome.
    Cascio JA; Walsh M; Hoenig K; Davis B
    Ann Allergy Asthma Immunol; 2022 Aug; 129(2):254-255. PubMed ID: 35537650
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab.
    Leon-Ferre RA; Weiler CR; Halfdanarson TR
    Clin Adv Hematol Oncol; 2013 May; 11(5):317-9. PubMed ID: 23880717
    [No Abstract]   [Full Text] [Related]  

  • 9. Familial clustering of hypereosinophilic diseases treated with mepolizumab: a case report from Japan.
    Kurosawa M; Sutoh Y; Sutoh E
    Eur Ann Allergy Clin Immunol; 2020 Jan; 52(1):39-44. PubMed ID: 31594295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypereosinophilic syndrome and mepolizumab.
    Boulware DR; Stauffer WM; Walker PF
    N Engl J Med; 2008 Jun; 358(26):2839; author reply 2839-40. PubMed ID: 18589879
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypereosinophilic syndrome and mepolizumab.
    Boucher RM; Gilbert-McClain L; Chowdhury B
    N Engl J Med; 2008 Jun; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypereosinophilic syndrome and mepolizumab.
    Verzegnassi F
    N Engl J Med; 2008 Jun; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
    N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
    Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
    Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
    Koury MJ; Newman JH; Murray JJ
    Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
    [No Abstract]   [Full Text] [Related]  

  • 17. An unusual presentation of idiopathic hypereosinophilic syndrome.
    Thakral C
    Clin Adv Hematol Oncol; 2013 May; 11(5):320-1. PubMed ID: 23880718
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab.
    Buttgereit T; Bonnekoh H; Church MK; Bergmann KC; Siebenhaar F; Metz M
    J Dtsch Dermatol Ges; 2019 Nov; 17(11):1171-1172. PubMed ID: 31479567
    [No Abstract]   [Full Text] [Related]  

  • 19. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
    Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
    J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.